We are excited to share news of the publication of our co-authored article (with our partners at FasterCures, a Center of the Milken Institute and CureSearch for Children's Cancer) on how nonprofits can play a critical 'matchmaking' role in getting needed drugs to market for patients.
Many promising medicines, despite strong safety data and pharmaceutical characteristics, are discontinued by drug companies for nonscientific reasons, including strategic, organizational, and financial considerations. Gaining access to these shelved drugs—to investigate intended or new indications—is challenging. Meanwhile, patients and families wait for new therapies for their conditions (including NF).
A new approach to solving this challenge assigns patient advocacy groups and other nonprofit organizations as matchmakers between discontinued drug assets and capital sources. The lessons learned from piloting this approach offer a potential template for others focused on identifying and accessing discontinued assets for clinical development.
Click here to read the full article.
